Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Ixaltis, a start-up company focused on urogenital disorders, has raised $9 million in its first funding round. The French firm’s pipeline consists of three compounds licensed from Sanofi. The most advanced is litoxetine, a serotonin reuptake inhibitor and 5-HT3 receptor antagonist that Sanofi had studied as an antidepressant. Ixaltis will soon begin testing the compound in a Phase II trial for treating urinary incontinence. The company also received a $3.2 million loan under an academic-industrial research project dedicated to urogenital diseases.
This article has been sent to the following recipient: